Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects
Authors:
- Arne AstrupAAArne Astrup
- Ecopipam Obesity Study GroupEGEcopipam Obesity Study Group
Abstract
Objective: To evaluate the efficacy and safety of the selective dopamine D1/D5 antagonist ecopipam for the treatment of obesity.Research Methods and Procedures: Four randomized, double‐blind, multicenter trials compared ecopipam (n = 1667) and placebo (n = 1118) in obese subjects including type 2 diabetic subjects. Subjects received oral ecopipam 10, 30, or 100 mg daily for 12 weeks (Phase 2) or 50 or 100 mg daily for 52 weeks (Phase 3) combined with a weight loss program. Primary efficacy variables were the proportion of subjects with ≥5% weight loss from baseline at 12 weeks (Phase 2) or the distribution of percentage weight loss from baseline at 52 weeks (Phase 3).Results: In the Phase 2 study, 26% of subjects administered ecopipam 100 mg vs. 6% of placebo subjects achieved ≥5% weight loss after 12 weeks (p < 0.01). In the Phase 3 studies, ecopipam 100 mg produced a 3.1% to 4.3% greater weight loss than placebo at 52 weeks. More subjects administered ecopipam vs. placebo achieved a 5% to 10% or >10% weight loss in two non‐diabetic phase 3 trials. Ecopipam‐treated subjects also maintained more weight loss compared with placebo subjects at 52 weeks. Phase 3 studies were discontinued because of unexpected psychiatric adverse events (ecopipam 31% vs. placebo 15%), including depression, anxiety, and suicidal ideation.Discussion: Ecopipam was effective for achieving and maintaining weight loss in obese subjects, including type 2 diabetic subjects; however, the adverse effects on mood observed in the Phase 3 studies exclude its projected use in weight management.Keywords
This publication has 36 references indexed in Scilit:
- Prevalence of obesity in IranObesity Reviews, 2005
- Prevalence of obesity in the United StatesObesity Reviews, 2005
- Prevention Conference VIICirculation, 2004
- Prevalence of obesity in UruguayObesity Reviews, 2004
- Psychological Functioning of Obese IndividualsDiabetes Spectrum, 2003
- Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166)Behavioural Pharmacology, 2003
- Attenuation of sucrose reinforcement in dopamine D1 receptor deficient miceEuropean Journal of Neuroscience, 2003
- Brain monoamine receptors in a chronic unpredictable stress model in ratsJournal of Neural Transmission, 2001
- A health status assessment of the impact of weight loss following Roux-en-Y gastric bypass for clinically severe obesityJournal of the American College of Surgeons, 1999
- Microdialysis Studies of Brain Norepinephrine, Serotonin, and Dopamine Release During Ingestive Behavior Theoretical and Clinical ImplicationsaAnnals of the New York Academy of Sciences, 1989